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Aims Temperature preconditioning (TP) provides very powerful protection against ischaemia/reperfusion. Understanding
the signalling pathways involved may enable the development of effective pharmacological cardioprotection. We
investigated the interrelationship between activation of protein kinase A (PKA) and protein kinase C (PKC) in the
signalling mechanisms of TP and developed a potent pharmacological intervention based on this mechanism.
Methods
and results
Isolated rat hearts were subjected to TP, 30 min global ischaemia, and 60 min reperfusion. Other control and TP
hearts were perfused with either sotalol (b-adrenergic blocker) or H-89 (PKA inhibitor). Some hearts were pre-
treated with either isoproterenol (b-adrenergic agonist) or adenosine (PKC activator) that were given alone, simul-
taneously, or sequentially. Pre-treatment with isoproterenol, adenosine, and the consecutive isoproterenol/adenosine
treatment was also combined with the PKC inhibitor chelerythrine. Cardioprotection was evaluated by haemo-
dynamic function recovery, lactate dehydrogenase release, measurement of mitochondrial permeability transition
pore opening, and protein carbonylation during reperfusion. Cyclic AMP and PKA activity were increased in TP
hearts. H-89 and sotalol blocked the cardioprotective effect of TP and TP-induced PKC activation. Isoproterenol,
adenosine, and the consecutive treatment increased PKC activity during pre-ischaemia. Isoproterenol signiﬁcantly
reduced myocardial glycogen content. Isoproterenol and adenosine, alone or simultaneously, protected hearts but
the consecutive treatment gave the highest protection. Cardioprotective effects of adenosine were completely
blocked by chelerythrine but those of the consecutive treatment only attenuated.
Conclusion The signal transduction pathway of TP involves PKA activation that precedes PKC activation. Pharmacologically
induced consecutive PKA/PKC activation mimics TP and induces extremely potent cardioprotection.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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1. Introduction
Reperfusion following a prolonged period of ischaemia induces myo-
cardial dysfunction and necrotic damage.
1 We have recently described
a novel cardioprotective protocol in which hearts are subject to a few
brief, transient hypothermic (268C) episodes interspersed with nor-
mothermic perfusion prior to index ischaemia. Such temperature
preconditioning (TP) is as good, if not better than ischaemic precon-
ditioning (IP) in restoring haemodynamic function and reducing
arrhythmias, oxidative stress, and lactate dehydrogenase (LDH)
release.
2 We showed that TP involves a modest increase in reactive
oxygen species (ROS) that activates protein kinase C1 (PKC1),
although AMP-activated protein kinase may play some role. The car-
dioprotective effects of TP, like IP,
3 were associated with decreased
oxidative stress at the end of ischaemia and during reperfusion. We
proposed that this prevents opening of the mitochondria permeability
transition pore (MPTP) leading to both improved contractile function
and decreased necrotic damage.
2
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Cardiovascular Research (2010) 88, 324–333
doi:10.1093/cvr/cvq190The switch from hypothermic to normothermic perfusion during
the TP protocol is accompanied by a rapid augmentation of haemo-
dynamic function that subsequently returns to the initial value.
2
These changes could reﬂect b-adrenergic stimulation following a TP
cycle with activation of cyclic AMP (cAMP)-dependent protein
kinase A (PKA) that others have shown to be cardioprotective.
4 In
this paper, we test this hypothesis and also study the temporal
relationship between PKA and PKC activation in TP hearts. We
demonstrate that PKA stimulation prior to PKC stimulation provides
optimal cardioprotection. Understanding the signalling pathways and
molecular targets through which TP exerts its effects may lead to
the development of more effective pharmacological interventions.
5
2. Methods
Unless otherwise stated, all biochemicals were from Sigma and general
chemicals from Fischer Scientiﬁc or VWR-Jencons.
2.1 Experimental procedures
2.1.1 Heart perfusion and analysis of haemodynamic
function
All procedures conform to the UK Animals (Scientiﬁc Procedures) Act
1986 and the Guide for the Care and Use of Laboratory Animals pub-
lished by the US National Institutes of Health (NIH Publication
No. 85-23, revised 1996). Ethical approval was granted by the University
of Bristol, UK (Investigator number ub/09/012). Male Wistar rats (250–
260 g) were killed by stunning and cervical dislocation. Hearts ( 0.75 g)
were rapidly removed into ice-cold Krebs–Henseleit buffer (KH) and per-
fused in Langendorff mode with haemodynamic measurements of left ven-
tricular developed pressure (LVDP), LV systolic pressure, LV end-diastolic
pressure, work index (RPP), heart rate (HR), and time derivatives of
pressure during contraction (+dP/dt) and relaxation (2dP/dt)a s
described previously
6 and detailed in Supplementary Methods.
2.1.2 Experimental groups
Four series of experiments were performed as shown schematically in
Figure 1. Further details are provided in Supplementary Methods. In brief,
after pre-ischaemia, global normothermic ischaemia (37
8C) was induced
for 30 min and then normothermic perfusion reinstated for 60 min. In
Series 1, hearts were divided into two groups: control (15 hearts) and
TP (12 hearts). TP hearts experienced three cycles of 2 min hypothermic
perfusion at 26
8C interspersed with 6 min normothermic perfusion prior
to ischaemia. Samples of perfusate were collected for determination of
LDH activity. Eight and six additional hearts of each group were freeze-
clamped following 44 min pre-ischaemia and 15 min reperfusion, respect-
ively, ground under liquid nitrogen, and stored at 2808C for later analysis
of cAMP, PKA activity, and Akt and GSK3 phosphorylation.
InSeries2(Figure1B),sixgroupsofsixtoeightheartswereemployed;three
controlgroups(C,CS,andCH)andthreeTPgroups(TP,TPS,andTPH)inthe
presence or absence of 10 mM of the non-selective b-adrenergic blocker
sotalol (CS and TPS) or 10 mM H-89 (PKA inhibitor) (CH and TPH).
Sotalol and H-89 were washed out for 5 min before index ischaemia. Eight
additionalheartsofC,CH,TP,andTPHgroupswerefreeze-clampedfollow-
ing 51 min pre-ischaemia for further analysis of PKC activity.
In Series 3 (Figure 1C), hearts were perfused with either adenosine, a
PKC activator well known for its cardioprotective effects,
7 or isoproter-
enol, a non-selective b-adrenergic agonist widely used on isolated per-
fused heart. Hearts were divided into four groups (7–9 hearts in each):
control, hearts perfused with 0.2 mM isoproterenol for 2 min followed
by 10 min washout, hearts perfused with 30 mM adenosine for 5 min fol-
lowed by 5 min washout, and hearts perfused with isoproterenol followed
by perfusion with adenosine and 5 min washout. Eight additional
non-ischaemic hearts of each group were freeze-clamped following
27 min KH perfusion (control group) or immediately after isoproterenol
or adenosine treatment for later analysis of PKC activity. Eight more
frozen pre-ischaemic hearts were used for measuring myocardial glycogen
content in each group, whereas another 7–10 hearts of each group were
used to prepare mitochondria after 30 min global ischaemia for the
measurement of MPTP opening and analysis of protein carbonylation.
In Series 4 (Figure 1C), hearts were divided into eight groups (5–8 heats
each): Group 1 control; Groups 2–4, hearts subjected to either isopro-
terenol, adenosine, or consecutive isoproterenol and adenosine treat-
ment (see Series 3); in Groups 5–7, the PKC inhibitor chelerythrine
(10 mM) was added 5 min before isoproterenol (Groups 5 and 7) or ade-
nosine (Group 6) perfusion and removed prior to ischaemia. Chelerythr-
ine at this concentration has no effect on heart recovery during
reperfusion.
2 Hearts of Group 8 were perfused with 30 mM adenosine
for 5 min with 0.2 mM isoproterenol also added after 1.5 min for 2 min.
Figure 1 Outline of the protocols used in the experiments.
(A) Series 1. TP, temperature preconditioning; C, control.
(B) Series 2. CS and CH, control hearts perfused with 10 mM
sotalol or H-89, respectively. TPS and TPH, TP hearts perfused
with 10 mM sotalol or H-89, respectively. (C) Series 3 and 4. Iso,
hearts perfused with 0.2 mM isoproterenol (2 min, 378C) + 10 min
washout; Ade, hearts perfused with 30 mM adenosine (5 min,
378C) + 5 min washout; consecutive Iso + Ade, hearts perfused
with isoproterenol then adenosine + 5 min washout; mixed
Iso + Ade, 2 min perfusion with 0.2 mM isoproterenol during
5 min perfusion with 30 mM adenosine followed by 5 min washout.
In Series 4, Iso, Ade, and the consecutive Iso + Ade treatments
were also combined with 10 mM chelerythrine infusion started
5 min before perfusion with isoproterenol or adenosine and com-
pleted at the end of pre-ischaemia.
Cardioprotection by consecutive PKA/PKC activation 3252.1.3 Assays
PKA and PKC activities and cAMP concentration were determined in
freeze-clamped heart powders using kits supplied by Sigma (cAMP) and
Promega (PKA and PKC) according to the manufacturer’s instructions.
The assays of PKA and PKC activity rely on a change in charge of the ﬂu-
orescent PepTag
w A1 and PepTag
w C1 peptides from +1t o21 follow-
ing phosphorylation. Bands were visualized under UV light and the ratio of
ﬂuorescence intensity of phosphorylated to non-phosphorylated peptide
was quantiﬁed using AlphaInotech ChemiImager 4400 with AlphaEase
v5.5 software. The phosphorylation of Akt and GSK3a/b was determined
in freeze-clamped, powdered hearts by a method based on that of
Hausenloy et al.
8 using western blotting with antibodies (Cell Signaling
Technology) against phosphorylated and total Akt and GSK3a/b. The
ratio of the band intensity for phosphoprotein to total protein was
used as a measure of phosphorylation state.
The assay of glycogen in freeze-clamped pre-ischaemic hearts was per-
formed using a-glycosidase hydrolysis with measurement of the released
glucoseperformedspetrophotometrically(340 nm)asdescribedpreviously.
9
Mitochondria were isolated as described in Supplementary Methods and
measurement of MPTP opening performed in de-energized conditions at
308C as described previously
3 using the decrease in light scattering (A520)
that accompanies mitochondrial swelling following addition of 100 mM
Ca
2+.
Protein carbonyls were determined in frozen mitochondria following
derivatization with dinitrophenylhydrazine (Chemicon International,
Chandlers Ford, UK) and western blotting with anti-dinitrophenyl anti-
bodies (Sigma) exactly as described previously.
10
Further details may be found in Supplementary Methods.
2.2 Statistical analysis
Data are presented as mean+SEM. Statistical signiﬁcances of the differ-
ences between groups were evaluated using Student’s t-test (Series 1)
or one-way ANOVA followed by Tukey’s multiple comparison post hoc
test (Series 2–4) using GraphPad Prism v5.0 software. Differences were
considered signiﬁcant where P , 0.05.
3. Results
3.1 PKA activity and Akt/GSK3
phosphorylation following TP (Series 1)
In Table 1, we show that during reperfusion, recovery of LVDP and RPP
in TP hearts was two-fold greater than for control hearts with a 60%
increase in the time derivatives of LV pressure. Protection against
necrotic damage (LDH release) during the ﬁrst 15 min of reperfusion
showed a similar pattern to the recovery of haemodynamic function.
Figure 2 shows that after the TP protocol, the tissue concentration of
cAMP was signiﬁcantly increased (Figure 2B) as was PKA activity
(Figure 2A). However, neither GSK3a/b (Figure 2C and E) nor Akt
(Figure 2D and F) showed any change in phosphorylation following
the TP protocol or after 15 min reperfusion.
3.2 b-Adrenergic stimulation of PKA
is required for PKC activation and
cardioprotection by TP (Series 2)
The role of b-adrenergic stimulation and PKA activation in TP was
investigated using the b-adrenergic blocker (+)-sotalol
11 and the
PKA inhibitor H-89.
12 In preliminary experiments (data not shown),
we found that both 10 mM sotalol and 10 mM H-89 completely and
reversibly abolished the increase in haemodynamic function induced
by isoproterenol (0.2 mM).
Prior to ischaemia, the RPP of sotalol-treated hearts (TPS group)
was signiﬁcantly lower than untreated hearts during the ﬁrst and
third hypothermic episodes, and sotalol also suppressed the rise of
HR during the subsequent normothermia leading to a smaller increase
in RPP (Figure 3A). H-89 (TPH group) also decreased LVDP, although
HR of these hearts was higher than in the TPS hearts in all three nor-
mothermic episodes (Supplementary material online, Table S1). The
combined effect was a lower RPP in TPH hearts relative to TP
(Figure 3A), but less so than in TPS hearts. H-89 also blocked the
increase in PKC activity seen in TP hearts without affecting PKC
activity in control hearts (Figure 3B).
Neither sotalol (CS) nor H-89 (CH) affected recovery of LVDP or
RPP in control hearts but they did attenuate (sotalol, TPS group) or
prevent (H-89, TPH group) the increased haemodynamic recovery
seen in TP hearts. The effects of sotalol and H-89 on haemodynamic
function were matched by their ability to reduce or abolish the pro-
tection TP offers against necrosis (LDH release) (Table 2).
3.3 The consecutive pharmacological
activation of PKA and PKC induced
powerful cardioprotection (Series 3 and 4)
3.3.1 Pre-ischaemic effects
Adenosine reduced RPP by  20% (P , 0.05) with subsequent gradual
return of this parameter to the initial value, whereas perfusion with
...........................................................................................
.......................................................................................................................................................................................
Table 1 Effects of TP on haemodynamic function and LDH release from the hearts during reperfusion
Parameters Pre-ischaemia (n 5 27) Reperfusion
Control (n 5 15) TP (n 5 12)
LVDP (mmHg) 80.7+3.9 % of initial values 30.4+3.6 69.8+7.7***
HR (b.p.m.) 302.0+5.2 100.4+3.3 97.6+2.4
RPP (mmHg b.p.m) 24273+1164 31.3+4.2 67.0+6.7***
+dP/dt (mmHg/s) 3697+145 45.5+3.5 71.6+6.2**
2dP/dt (mmHg/s) 2984+132 52.2+4.3 84.2+5.8***
LDH (mU/mL perfusate) 1.9+0.2 5 min 24.7+3.3 13.6+2.1*
10 min 25.0+4.8 13.2+2.0*
15 min 24.5+4.2 11.8+2.2*
Haemodynamic function was determined prior to ischaemia and after 60 min reperfusion. LDH release was measured prior to ischaemia and during the ﬁrst 15 min of reperfusion.
*P , 0.05, **P , 0.01, ***P , 0.001 vs. control.
I. Khaliulin et al. 326isoproterenol increased RPP 2.5-fold. When hearts perfused with iso-
proterenol were switched to adenosine, RPP was reduced to 60% of
the initial value (P , 0.01) and was signiﬁcantly lower than in
adenosine-treated hearts (P , 0.01). At the end of pre-ischaemia,
this parameter was still slightly decreased in hearts of the consecutive
isoproterenol + adenosine group (P , 0.05 vs. initial value)
(Figure 4A). Perfusion with isoproterenol but not adenosine also
reduced the glycogen content of the hearts by .50%. There was
no additive effect of adenosine on the response to isoproterenol
(Figure 4B). PKC activity, measured immediately after perfusion with
isoproterenol or adenosine, was signiﬁcantly higher in all three
groups of isoproterenol and adenosine-treated hearts (Figure 4C).
3.3.2 Cardioprotection is associated with inhibition of
protein carbonylation and MPTP opening on reperfusion
Treatment of hearts with either isoproterenol or adenosine alone
improved haemodynamic function recovery after 30 min global
ischaemia and 60 min reperfusion (Table 3); the recovered LVDP
and RPP reached twice the values of control reperfused hearts.
However, consecutive treatment of hearts with isoproterenol fol-
lowed by adenosine resulted in a complete recovery of haemo-
dynamic function accompanied by the lowest LDH release (Table 3).
Haemodynamic function recovery of hearts treated simultaneously
(as opposed to consecutively) with the mixture of adenosine and iso-
proterenol (Table 4) was similar to hearts treated with isoproterenol
Figure 2 Effect of TP on PKA activity, cAMP concentration, and Akt/GSK3 phosphorylation. (A) PKA activity was measured using the PepTag
w assay
(Promega) and expressed as a ratio of ﬂuorescence intensity of phosphorylated and non-phosphorylated PepTag
w A1 peptide (P-A1 and A1, respect-
ively). (Inset) A representative gel containing A1 and P-A1; Neg C, negative control; Pos C, positive control (PepTag
w A1 peptide phosphorylated by
the PKA catalytic subunit). (B) cAMP concentration was determined using a direct enzyme immunoassay kit (Sigma). (C–F) GSK3 (C + E) and Akt
(D + F) phosphorylation were determined prior to ischaemia (C + D) or after 15 min reperfusion (E + F) by western blotting using the ratio of
band intensity of phosphorylated to total protein. Eight hearts each of control (C) and temperature preconditioning (TP) groups were used for all
parameters. *P , 0.05 vs. control. Inset in each of (C–F): representative blots of phosphorylated (P) and total (T) GSK3 and Akt.
Cardioprotection by consecutive PKA/PKC activation 327or adenosine alone and signiﬁcantly lower than for consecutive treat-
ment. The PKC inhibitor chelerythrine completely abolished the
improvement of haemodynamic function recovery in adenosine-
treated hearts and considerably reduced the beneﬁcial effect of the
consecutive isoproterenol and adenosine treatment but had no signiﬁ-
cant effect on the recovery of isoproterenol-treated hearts. LDH
release was the lowest in hearts with the consecutive treatment
(Tables 3 and 4); in hearts with the simultaneous isoproterenol and
adenosine treatment this parameter was not signiﬁcantly less than
controls (Table 4). In hearts treated with the combination of adeno-
sine and chelerythrine, LDH release was the same as control.
Both isoproterenol and adenosine reduced Ca
2+-induced mito-
chondria swelling (MPTP opening) after 30 min global ischaemia to
17 and 41% of control ischaemic values, respectively, whereas the
sequential treatment with the two agents reduced swelling to 5%
Figure 3 Effect of sotalol and H-89 on RPP and PKC activity of
control and TP hearts prior to ischaemia. (A) Mean data for RPP
measured during hypothermic and normothermic perfusion in TP
(n ¼ 8), TP + 10 mM sotalol (TPS; n ¼ 6), and TP + 10 mM H-89
(TPH; n ¼ 6) hearts. RPP values for TPH and TPS groups were sig-
niﬁcantly lower (P , 0.05) than TP during all three episodes of nor-
mothermic perfusion. (B) Mean data for PKC activity measured in
eight hearts each of control (C), TP, control + 10 mM H-89 (CH),
and TPH groups. PKC activity was measured using non-radioactive
PepTag
w assay and is expressed as a ratio of ﬂuorescence intensity
of phosphorylated and non-phosphorylated peptide. *P , 0.05,
**P , 0.01 vs. TP. (Inset) Representative gels containing non-
phosphorylated and phosphorylated PepTag
w C1 peptide (C1 and
P-C1, respectively). Speciﬁcity of the PepTag
w C1 peptide to PKC
was conﬁrmed by its reaction with PKC control enzyme (Pos C,
positive control) and a heart sample (S). No phosphorylated
peptide was found without the control enzyme (Neg C, negative
control) or with the boiled heart sample (S-B).
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I. Khaliulin et al. 328indicating almost total prevention of MPTP opening (Figure 5A). Paral-
lel measurements of mitochondrial protein carbonylation showed that
only the consecutive isoproterenol + adenosine group gave a signiﬁ-
cant reduction in this parameter (Figure 5B).
4. Discussion
4.1 The signal transduction pathways of TP
4.1.1 Role of PKA activation
Here, we report that a b-adrenergic-mediated rise in cAMP and sub-
sequent activation of PKA is important for TP-induced cardioprotec-
tion which is consistent with our earlier observation
2 that the switch
from hypothermic perfusion to normothermia during TP caused a fast
and signiﬁcant augmentation of haemodynamic function (see also
Figure 4 Effect of isoproterenol and adenosine on RPP, glycogen
content, and PKC activity in the hearts prior to ischaemia. (A)M e a n
data for RPP in 0.2 mM isoproterenol (Iso; n ¼ 7), 30 mMa d e n o s i n e
(Ade; n ¼ 8), and consecutive isoproterenol + adenosine
(C-Iso + Ade; n ¼ 11) hearts measured during pre-ischaemia follow-
ing the equilibration period. Isoproterenol signiﬁcantly increased and
adenosine reduced RPP compared with control hearts (C). The
decrease in RPP was signiﬁcantly greater in the C-Iso + Ade hearts
than in the Ade hearts (P , 0.05) starting from 27 min pre-ischaemia.
(B) Mean data for glycogen content in six hearts each of control C, Iso,
Ade, and C-Iso + Ade groups. ***P , 0.001 vs. control. (C)M e a n
data for PKC activity in six each of C, Iso, Ade, and C-Iso + Ade
groups measured in hearts prior to ischaemia. *P , 0.05 vs. control.
(Inset) A representative gel containing non-phosphorylated and phos-
phorylated PepTag
w C1 peptide (C1 and P-C1, respectively).
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Table 4 Comparison of the effects of chelerythrine and consecutive and simultaneous perfusion with isoproterenol and adenosine on haemodynamic function and LDH
release from the hearts during reperfusion
Parameters Pre-ischaemia
(n 5 46)
Reperfusion
Control
(n 5 8)
M-Iso 1 Ade
(n 5 6)
C-Iso 1 Ade
(n 5 5)
Che 1 (C-Iso 1
Ade) (n 5 7)
Iso (n 5 5) Che 1 Iso
(n 5 5)
Ade (n 5 5) Che 1 Ade
(n 5 5)
LVDP (mmHg) 79.3+3.0 % of initial
values
23.4+4.1 59.4+7.2**
,## 101.8+5.8*** 60.1+3.8***
,††† 58.7+8.5*
,## 47.0+5.7*
,### 47.5+1.7*
,### 25.7+1.6
†,###
HR (b.p.m.) 283.3+5.1 99.6+6.5 97.9+3.1 98.3+1.9 93.5+3.3 92.2+5.3 96.6+2.1 98.3+3.1 98.0+2.2
RPP (mmHg b.p.m.) 22411+903 22.7+3.5 57.8+6.8***
,### 100.2+6.7*** 55.7+2.7**
,††† 55.0+9.9*
,## 45.2+5.1*
,### 46.3+1.3 *
### 25.4+2.2
†,###
+dP/dt (mmHg/s) 2703+84 23.1+2.7 59.8+6.8**
,### 117.5+5.5*** 60.8+5.1***
,††† 60.4+9.1*
,## 49.4+6.5*
,### 46.8+3.7*
,### 26.1+0.6
†,###
2dP/dt (mmHg/s) 2150+103 24.3+3.4 52.9+5.8**
,### 99.0+5.2*** 43.1+5.1*
,††† 52.2+8.3* 39.5+8.4
### 43.5+1.0*
,### 33.5+2.7
†,###
LDH (mU/mL
perfusate)
1.3+0.1 5 min 10.3+1.8 7.8+2.0 3.6+0.8** 7.4+1.9 8.8+2.6 8.5+0.7 9.2+2.5 13.4+2.3
##
10 min 14.5+3.1 10.7+3.0 6.1+1.4* 7.2+3.0 7.7+2.6 8.3+1.2 10.8+2.5 13.3+2.3
#
15 min 12.8+3.1 10.1+2.2
# 3.8+1.3* 6.0+2.0 5.2+1.2 7.2+1.3 7.7+2.5 12.1+2.0
##
Haemodynamic function was determined prior to ischaemia and after 60 min reperfusion. LDH release was measured prior to ischaemia and during the ﬁrst 15 min of reperfusion. Iso, isoproterenol; Ade, adenosine; C-Iso + Ade, consecutive
treatment with Iso and Ade; M-Iso + Ade, mixed Iso and Ade treatment; Che, chelerythrine.
*P , 0.05, **P , 0.01, ***P , 0.001 vs. control.
#P , 0.05,
##P , 0.01,
###P , 0.001 vs. C-Iso + Ade.
†P , 0.05,
††P , 0.01,
†††P , 0.001 of a group of hearts treated with Che vs. a corresponding group non-treated with Che. Che (10 mM) had no effect on haemodynamic function and LDH release during reperfusion in control hearts.
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3
0online, Table S1; Figure 3A), whereas H-89 completely abolished and
sotalol partially abolished the TP-mediated improvement of haemo-
dynamic function and reduction of LDH release during reperfusion
(Table 2). These data suggest that b-adrenergic stimulation is only par-
tially responsible for PKA activation during TP protocol and that
another pathway, perhaps ROS-mediated,
14 may also be involved.
Indeed, we have shown previously that the free radical scavenger
N-(2-mercaptopropionyl)-glycine (300 mM) applied during
pre-ischaemia abolishes cardioprotection by TP as it does for IP.
2
Furthermore, Stowe and colleagues
15 have reported that hypothermia
moderately enhances superoxide concentration in myocardium.
Interestingly, it has been shown by others that b-adrenergic stimu-
lation can be considered as a trigger of IP
4 and that repeated stimu-
lation with norepinephrine or isoproterenol mimics IP.
16 Proposed
mechanisms for cardioprotection by b-adrenergic activation of PKA
include b-adrenergic desensitization
4 and attenuation of calpain-
mediated degradation pathways.
12
A major problem with using protein kinase inhibitors to dissect signal
transduction pathways is their lack of speciﬁcity.
17 Although H-89 is a
potent PKA inhibitor, it can inhibit other kinases including Akt.
17 The
Akt–GSK3 pathway has been implicated in cardioprotection by IP,
18
although our own data
3 and that of other
19 have questioned the
central role of this pathway prior to ischaemia and we were unable
to detect any change in phosphorylation of either protein following
the TP protocol (Figure 2C and D). Hausenloy et al.
8 showed IP-induced
Akt phosphorylation at 15 min of reperfusion following prolonged
ischaemia, but we were also unable to detect any changes in Akt or
GSK3 phosphorylation by TP at 15 min reperfusion (Figure 2E and F).
However, we cannot completely exclude involvement of this
pathway in TP because phosphorylation could be transient; although
in studies where Akt activation and GSK3 inhibition were found to
be important for cardioprotection, phosphorylation of these kinases
was very consistent and signiﬁcant during preischaemia
20 and reperfu-
sion.
8,21 Thus, our data do not support a major role of Akt and GSK3
phosphorylation in the TP signalling mechanism.
4.1.2 Sequential PKA and PKC activation during TP and
pharmacologically induced consecutive PKA/PKC activation
We have previously shown that PKC activation is critical for
TP-mediated cardioprotection,
2 and here, we demonstrate that the
PKA inhibitor H-89, which itself has little effect on PKC activity,
17 is
able to prevent both this PKC activation (Figure 3B) and cardioprotec-
tion (Table 2), implying that PKA activation is upstream of PKC acti-
vation in the TP signalling pathway. Our data further support this
ﬁnding. Thus, treatment of rat hearts consecutively with the
b-adrenergic agonist isoproterenol and then adenosine, to activate
PKC, resulted in extremely potent cardioprotection that considerably
exceeded the protection afforded by either agent alone (Table 3)o r
added simultaneously (Table 4) and allowed hearts to recover com-
pletely after 30 min normothermic (378C) global ischaemia. Thus,
the consecutive activation of these enzymes (PKA followed by PKC
activation) is of critical importance in terms of cardioprotection.
4.2 Mechanisms underlying the
cardioprotective effect of sequential
PKA/PKC activation
4.2.1 Glycogen breakdown
The decreased glycogen content found in isoproterenol-treated
hearts (Figure 4B) could contribute to the observed cardioprotective
effect. Thus, it has been reported that glycogen depletion of rat hearts
by anoxic perfusion prior to global ischaemia signiﬁcantly improved
recovery of ventricular function during reperfusion, whereas lactate
accumulation was harmful for the heart.
22 Others showed that IP is
associated with glycogen depletion leading to less anaerobic glycolysis
during the subsequent prolonged ischaemia, and hence reduced
accumulation of lactate and H
+. This causes a smaller decrease in
intracellular pH during ischaemia and thus less compensatory
increases in intracellular Na
+ and Ca
2+.
23 The decreased calcium
loading will reduce the likelihood that the MPTP opens which might
partially explain the observed cardioprotection.
24 However, reduced
glycogen content alone cannot entirely account for the cardioprotec-
tion in our experiments since this parameter was similar in hearts
treated with isoproterenol alone or with adenosine; yet, the com-
bined treatment gave much better protection. Our data suggest
that the additional factor is activation of PKC.
4.2.2 Involvement of PKC in cardioprotection
It has been shown that isoproterenol can augment the negative ino-
tropic effect of adenosine
25 which we also observed in the pre-
ischaemic phase of the combined treatment (Figure 4A). This would
be consistent with PKA activation of PKC, and in support of this,
our data show that perfusion with the b-adrenergic agonist isoproter-
enol does increase PKC activity in the heart (Figure 4C). Stimulation of
b-adrenergic receptors and PKA activates ROS production by mito-
chondria
26 and promotes accumulation of intracellular Ca
2+
([Ca
2+]i).
27 Meanwhile, it has been found that ROS may trigger
PKC activation
28 and increase in [Ca
2+]i could also activate PKC via
direct Ca
2+-dependent activation or via a G-protein activated by
Ca
2+-dependent phospholipase C.
29
The cardioprotective effect of PKC activation (primarily PKC1)i s
well established
7 and we have also shown recently that urocortin-
induced reduction of oxidative stress is mediated by PKC resulting
in MPTP inhibition during reperfusion.
30 How this is achieved
remains unclear. It has been reported that PKC1 may phosphorylate
the voltage-dependent anion channel in the outer mitochondrial
membrane or prevent binding of cyclophilin D to adenine nucleotide
translocase which results in inhibition of MPTP,
31 although our
own data failed to detect these changes in IP.
3 PKC may also
phosphorylate the BH3-only protein Bad
32 which increases the
availability of Bcl-2 for antioxidant and anti-apoptotic functions.
33
Whatever the mechanism, it appears that PKC1 activation prevents
ROS production and MPTP opening during ischaemia and
reperfusion.
We have previously found that the PKC inhibitor chelerythrine
abrogated TP-induced cardioprotection,
2 and here, we show
(Table 4) that chelerythrine completely abolished the protective
effect of adenosine and considerably reduced cardioprotection
afforded by the consecutive isoproterenol/adenosine treatment.
However, chelerythrine had little effect on the protective effect of
isoproterenol. These results suggest that PKA-induced cardioprotec-
tion in our experiments did not rely exclusively on PKC activation but
was associated with other mechanisms including glycogen depletion
prior to ischaemia. Our data also show that the strong protective
effect of the consecutive isoproterenol/adenosine treatment was
rather a result of the synergic action of both PKA and PKC than
PKC being the only effector in the signalling mechanisms of this
pharmacological treatment.
Cardioprotection by consecutive PKA/PKC activation 3314.2.3 Decreased oxidative stress and reduced MPTP opening
We demonstrated previously that protection by TP involves inhibition
of MPTP opening.
2 Here, we show that consecutive treatment of the
heart with isoproterenol and adenosine also dramatically reduced
calcium-induced mitochondria swelling, an indicator of MPTP
opening (Figure 5A). Treatment with isoproterenol or adenosine
alone also gave a signiﬁcant, but smaller, reduction in calcium-induced
mitochondria swelling. This is of interest because it was demonstrated
more than 30 years ago that mitochondria isolated from livers treated
with glucagon, dibutyryl-cAMP or a-adrenergic agonists (PKC activat-
ing) retained accumulated calcium for longer than those from control
livers.
34–36 This increase in ‘calcium retention time’ is now known to
reﬂect an inhibition of MPTP opening and thus it appears likely that a
similar cAMP-dependent protective mechanism to that seen in the
heart also operates in liver.
For both IP and TP, inhibition of the MPTP in mitochondria isolated
at the end of ischaemia or during reperfusion correlates with a
decreased oxidative stress as reﬂected in protein carbonylation,
2,3
and here, we show that the powerful protective effect of the sequen-
tial isoproterenol + adenosine treatment was also accompanied by a
signiﬁcant decrease in protein carbonylation (Fig 5B). Treatment with
each agent on its own also showed a slight reduction in protein car-
bonylation but this was not statistically signiﬁcant. No published data
are available on the effects of glucagon or a-adrenergic agonists on
liver mitochondrial protein carbonylation, but glucagon was found
to decrease mitochondrial lysophospholipid accumulation
37 consist-
ent with reduced lipid peroxidation,
38 another indicator of oxidative
stress. Thus, it is possible that the inhibition of MPTP opening by
cAMP-dependent mechanisms in liver, as well as in TP and particularly
isoproterenol + adenosine-treated hearts, involves a decrease in oxi-
dative stress.
4.3 Conclusions
The novel ﬁndings of our study are as follows. First, PKA activation,
like PKC activation, is a very important link in the signalling mech-
anism of TP with PKA activation being upstream of PKC activation
a n dm e d i a t e di np a r tb yb-adrenergic stimulation. Secondly,
pharmacologically induced consecutive PKA and PKC activation
provides potent cardioprotection. Thirdly, this cardioprotection is
associated with depletion of myocardial glycogen prior to ischae-
mia which may lead to less calcium loading during ischaemia.
This, together with the reduction of oxidative stress during ischae-
mia, will lead to less MPTP opening and thus better recovery
during reperfusion. This pharmacological strategy may represent a
promising protocol for heart protection during prolonged ischae-
mia and reperfusion such as in open heart surgery or
transplantation.
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